Trade Names:Ponstel- Capsules 250 mgApo-Mefenamic (Canada)
Decreases inflammation, pain, and fever, probably through inhibition of cyclooxygenase activity and prostaglandin synthesis.
Relief of moderate pain lasting less than 1 wk; treatment of primary dysmenorrhea.
Treatment of sunburn, migraine (acute attack), PMS.
Patients in whom aspirin, iodides, or any NSAID has caused allergic-type reactions; preexisting renal disease; active ulceration or chronic inflammation of GI tract.
PO 500 mg, followed by 250 mg every 6 h as needed. Usually not used more than 1 wk.Primary DysmenorrheaAdults and Children (14 yr of age and older)
PO 500 mg, followed by 250 mg every 6 h starting with onset of bleeding and associated symptoms.
Store at room temperature (59° to 86°F) in tightly closed, light-resistant container.
Increased risk of gastric erosion and bleeding.Cyclosporine
Nephrotoxicity of both agents may be increased.CYP-450
Exercise caution when coadministering mefenamic acid with drugs known to inhibit the isoenzyme 2C9.Lithium
Serum lithium levels may be increased.Methotrexate
Increased methotrexate levels.Salicylates
Additive GI toxicity.
May cause prolonged bleeding time or false-positive reaction for urinary bile using diazo tablet test.
Edema; weight gain; CHF; altered BP; palpitations; chest pain; bradycardia; tachycardia.
Headache; vertigo; drowsiness; dizziness; insomnia.
Rash; urticaria; purpura.
Blurred vision; tinnitus; salivation; glossitis.
Diarrhea; dry mouth; vomiting; abdominal pain; dyspepsia; GI bleeding; nausea; constipation; flatulence.
Hematuria; proteinuria; dysuria; renal failure.
Decreased hematocrit; bleeding; neutropenia; leukopenia; pancytopenia; eosinophilia; thrombocytopenia.
Mild elevations in LFT results.
Bronchospasm; laryngeal edema; rhinitis; dyspnea; pharyngitis; hemoptysis; shortness of breath.
Autoimmune hemolytic anemia may occur if used long term.
Category C .
Not recommended for children younger than 14 yr of age.
Increased risk of adverse reactions.
May occur; use with caution in aspirin-sensitive individuals because of possible cross sensitivity.
Acute renal insufficiency, interstitial nephritis, hyperkalemia, hyponatremia, and renal papillary necrosis may occur. Lower doses may be necessary in patients with renal function impairment.
If diarrhea occurs, reduce dosage or temporarily discontinue.
Bleeding, ulceration, or perforation can occur at any time, with or without warning symptoms.
Promptly discontinue if rash develops.
Acute renal failure, coma, grand mal seizures, muscle twitching, status epilepticus.
Copyright © 2009 Wolters Kluwer Health.